The impressive success of T-DXd has prompted the initiation of multiple clinical trials aimed at assessing its potential synergies with immune checkpoint inhibitors, endocrine therapy, and chemotherapy, among other therapeutic modalities, in the treatment of low HER2 breast cancer (NCT04556773). This evidence concerns the gene ERBB2 and breast carcinoma.